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Abstract
Background: The apolipoprotein E ɛ4 (APOE4) allele is the strongest genetic risk factor identified for developing
Alzheimer’s disease (AD). Among brain lipids, alteration in the ω-3 polyunsaturated fatty acid docosahexaenoic acid
(DHA) homeostasis is implicated in AD pathogenesis. APOE4 may influence both brain DHA metabolism and
cognitive outcomes.
Methods: Using positron emission tomography, regional incorporation coefficients (k*), rates of DHA incorporation
from plasma into the brain using [1-11C]-DHA (Jin), and regional cerebral blood flow using [
15O]-water were measured
in 22 middle-aged healthy adults (mean age 35 years, range 19–65 years). Data were partially volume error-corrected
for brain atrophy. APOE4 phenotype was determined by protein expression, and unesterified DHA concentrations were
quantified in plasma. An exploratory post hoc analysis of the effect of APOE4 on DHA brain kinetics was performed.
Results: The mean global gray matter DHA incorporation coefficient, k*, was significantly higher (16%) among APOE4
carriers (n = 9) than among noncarriers (n = 13, p = 0.046). Higher DHA incorporation coefficients were observed in
several brain regions, particularly in the entorhinal subregion, an area affected early in AD pathogenesis. Cerebral blood
flow, unesterified plasma DHA, and whole brain DHA incorporation rate (Jin) did not differ significantly between the
APOE groups.
Conclusions: Our findings suggest an increase in the DHA incorporation coefficient in several brain regions in APOE4
carriers. These findings may contribute to understanding how APOE4 genotypes affect AD risk.
Keywords: APOE, Alzheimer’s disease, DHA, PET
Background
Apolipoprotein E ɛ4 (APOE4) genotype is the strongest
genetic risk factor for late-onset or sporadic Alzheimer’s
disease (AD). APOE proteins, the product of the APOE
gene, have isoform-specific functions. For example,
APOE’s affinity for the low-density lipoprotein receptor
is known to differ between isoforms (APOE4 > APOE3 >
APOE2) [1]. These differences have implications for the
metabolism of APOE lipoprotein particles and the
amount of lipid carried by APOE. In the brain, APOE
forms high-density lipoprotein particles and participates
in exchange of lipids between glial cells and neurons [2].
Clinical and animal studies indicate that brain APOE
particle size and number differ by APOE genotype [3–5].
In plasma, APOE4 is catabolized faster with a plasma
residence time of approximately half that of APOE3 [6].
Among brain lipids, the ω-3 polyunsaturated fatty acid
(PUFA) docosahexaenoic acid (DHA, 22:6ω-3) may be of
particular importance in AD pathogenesis. DHA forms
up to 40% of fatty acids in certain gray matter lipids and
is concentrated at synapses, where it plays a role in syn-
aptic plasticity [7]. In embryonic neuronal cultures,
DHA supplementation promotes neurite growth and
synaptic protein expression [8]. Severe long-term dietary
deficiency of DHA leads to learning impairment in ani-
mal models [9]. The brain also requires DHA for main-
tenance of neuronal membranes, production and
clearance of β-amyloid 42, modulation of inflammation
[10, 11], and cerebrovascular health [12]. We previously
reported a direct association between lower serum DHA
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levels and greater cerebral amyloidosis in cognitively
healthy older adults [13]. The lowest quartile of serum
DHA was associated with significantly greater cerebral
amyloid deposition, smaller entorhinal and hippocampal
volumes, and worse nonverbal memory scores [13].
DHA’s incorporation into the brain can be assessed by
positron emission tomography (PET) following intraven-
ous infusion of carbon-11 ([1-11C])-DHA using the in-
corporation coefficient k* [14]. k* represents multiple
steps, including DHA diffusion from plasma to brain cells,
intracellular DHA acylation to DHA-CoA by an acyl-
coenzyme A (acyl-CoA) synthetase, and DHA transfer
from DHA-CoA to membrane lysophospholipids by an
acyltransferase [15]. k* is independent of changes in re-
gional cerebral blood flow (rCBF). For example, rCBF can
be doubled using CO2 inhalation without changing k*
[16]. The net rate of DHA incorporation from plasma (Jin)
is the product of unesterified plasma DHA times k*. At
steady state, Jin is equivalent to the net loss of DHA from
the brain (Jout). Chronic dietary ω-3 PUFA deprivation
leads to increased k* in the face of a 40-fold reduction in
the rate of DHA loss (Jout) from the brain [17].
APOE genotype may influence the metabolism of
DHA in the brain or its delivery to the brain, although
brain DHA delivery may not directly depend on periph-
eral lipoproteins [18]. In humans, whole body DHA half-
life was lower in APOE4 carriers than in noncarriers,
which was attributed to greater liver oxidation of DHA
[19]. Brain DHA levels were lower in older but not
younger APOE4 targeted replacement (TR) mice than in
age-matched APOE2 TR mice [20]. We found lower
cerebrospinal fluid (CSF) DHA levels in older APOE4
carriers with mild AD after 18 months of DHA supple-
mentation than in APOE4 noncarriers [21]. The goal of
the present study was to explore the effect of APOE4 on




We obtained plasma samples from 22 healthy control
subjects between 19 and 65 years of age to assess
APOE4 expression and APOE plasma levels. These
subjects were recruited from the Bethesda, MD, USA,
area [22]. The present report describes results from
the control arm only of an alcohol withdrawal study.
Participants were nonsmokers and reported no medi-
cation, drug, or alcohol use for at least 2 weeks prior
to the PET scan. All participants underwent an exten-
sive history and physical examination with laboratory
tests to ensure that they were free of significant med-
ical problems and had no history of neurological or
psychiatric disorders. Three days preceding the PET
scan, participants were instructed to avoid foods high
in ω-3 PUFAs (e.g., seafood). The Diet History Ques-
tionnaire was used to assess dietary habits 12 months
preceding the study [23].
PET imaging
The PET protocol involved first injecting a bolus of
[15O]-water to image rCBF. PET scans were acquired
at approximately 11:00 a.m. following 24 h on a stan-
dardized low-DHA diet and an overnight fast. Blood
was collected three times during the scan to quantify
plasma unesterified fatty acid concentrations and
tracer radioactivity. Fifteen minutes following the in-
jection of [15O]-water, 1118 MBq of [1-11C]-DHA was
infused intravenously for 3 minutes at a constant rate
(Harvard Infusion Pump, South Natick, MA, USA).
Because of the high specific activity of [1-11C]-DHA,
less than 0.06 mmol of unlabeled DHA was infused
into a subject, so there was no significant pharmaco-
logical or tracee effect of the dose of the tracer itself.
Serial dynamic three-dimensional scans were acquired
during the hour following the start of the infusion.
Arterial samples (2–5 ml) were obtained at fixed
times to determine radioactivity in whole blood and
plasma.
Input function
To rapidly assay plasma [1-11C]-DHA during a PET
scan, a solid-phase extraction procedure to separate
unesterified [1-11C]-DHA from remaining plasma
radioactivity was used. From plasma samples collected
at 0, 3, 7, 10, 15, 20, 40, and 60 minutes after infu-
sion of [1-11C]-DHA, total lipids were extracted into
chloroform:methanol (1:1) as previously described [24].
Coregistration of PET scans to brain anatomy
Magnetic resonance imaging (MRI) scans of the brain
were obtained with a 1.5-Tesla Horizon scanner (GE
Medical Systems, Milwaukee, WI, USA). This pro-
duced T1-weighted volumetric spoiled gradient MRI
scans for superimposition onto the PET images and
to register both rCBF images from the [15O]-water
scans and [1-11C]-DHA parametric images. Appropri-
ate coregistration of the PET images onto the MRI
studies was visually verified for each participant. Be-
cause of the poor spatial resolution of a PET scan,
underestimation of higher radioactivity can occur in
gray matter regions. To provide the most accurate
measure of radioactivity in specific gray matter re-
gions, partial volume error (PVE) was corrected. PVE
correction is particularly important when studying
disorders associated with cerebral atrophy, such as
aging, cognitive decline, and AD. It provides a better
measure of actual tissue metabolism or blood flow free of
effects of CSF, and it corrects for loss (spill-out) of the
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radioactive signal to adjacent tissue and for spill-in of sig-
nal from adjacent tissue.
Regions of interest
Following injection of [1-11C]-DHA, k* (μl/minute/ml)
was calculated from the PVE-corrected PET brain im-
ages using a one-tissue compartment model as described
previously [24]. Two approaches were used to perform
the image analysis. First, regions of interest (ROIs) were
drawn manually on individual MRI scans on six continu-
ous axial MRI slices at the National Institutes of Health
PET center [24]. PVE-corrected values of k* and rCBF
were obtained for all regions from PET images by limit-
ing averaging to voxels identified as gray matter by the
segmentation procedure. Second, T1-weighted MRI
FreeSurfer segmentation was used for the kinetic ana-
lysis of ROIs of the [1-11C]-DHA cerebral dynamic ac-
quisitions from 21 of the 22 participants at the
University of Sherbrooke, Sherbrooke, QC, Canada. Fig-
ure 1 presents an illustration of [1-11C]-DHA k* focused
in the entorhinal cortex area of one of the participants.
APOE phenotyping and ApoE plasma levels
APOE4 phenotype was obtained by Western blotting of
plasma samples using a previously validated APOE4-
specific antibody (8941S; Cell Signaling Technology,
Danvers, MA, USA). The validity of the antibody was
confirmed using samples of known APOE genotype.
APOE4 status was defined by visible APOE4 bands after
Western blotting of plasma samples. APOE plasma
levels were measured using an in-house enzyme-linked
immunosorbent assay with inter- and intraassay coeffi-
cients of variation <10% [25].
Data analysis
Data are presented as means with SDs. The two APOE
groups were compared using an independent t test or
linear regression modeling to adjust for covariates. Age
and sex were added to the linear model as covariates
with k* as the dependent variable and APOE group as
the independent variable. The variables were correlated
using Pearson’s correlations for normally distributed data
or Spearman’s correlations for nonnormally distributed
data. Within the brain regions, we focused on the medial
temporal lobe subregions, given their significance in AD,
with FreeSurfer segmentation to assess ROI [1-11C]-




Our study sample included 13 APOE4-negative and 9
APOE4-positive participants, based on the detection of
APOE4 proteins in plasma by Western blotting. The
participants were mostly middle-aged white individuals
who were not obese and were without diabetes or dyslip-






Fig. 1 FreeSurfer segmentation (green = right hemisphere, blue= left hemisphere) of the entorhinal region of interest superimposed on a sum image
(60 minutes) of [11C]-docosahexaenoic acid ([1-11C]-DHA) and T1-weighted magnetic resonance imaging scans of one participant. DHA incoporation
coefficient k* in the entorhinal cortex is illustrated in the red rectangles
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APOE genotype. Additional characteristics and biochem-
ical measurements are presented in Table 1.
DHA incorporation coefficient, k*
The mean global gray matter k* was 16% higher in APOE4
carriers than in noncarriers (p = 0.04) (Fig. 2a). k* was sig-
nificantly higher in several gray matter subregions
(Table 2), but it did not differ in the white matter by APOE
subgroup. Age did not correlate with k* (r = −0.006, p =
0.9), but only 4 of the 23 participants were older than
50 years of age. BMI (r = −0.04, p = 0.89) and sex (p = 0.8)
also did not correlate with k*. Including age (p = 0.12) or
sex (p = 0.1) attenuated the effect of APOE on global gray
matter k*. The k* in the medial temporal lobe was 17%
higher in APOE4 carriers than in noncarriers (p = 0.035)
(Fig. 2b). On the basis of FreeSurfer segmentation for the
kinetic analysis of ROI of the [1-11C]-DHA dynamic ac-
quisitions in the medial temporal lobe, the most pro-
nounced difference in k* was observed in the right
entorhinal region (34% greater in APOE4 carriers than in
noncarriers; p = 0.05) (Table 3). A significant inverse cor-
relation was observed between k* and blood volume in the
medial temporal lobe (r = −0.42, p = 0.05).
DHA incorporation rate (Jin)
The brain incorporation rate of DHA (Jin) was calculated
using the global gray matter (average of 19 gray matter
regions) value for k* before PVE correction multiplied
by plasma unlabeled unesterified DHA concentrations.
Unesterified plasma DHA concentrations were not dif-
ferent between APOE4 noncarriers and APOE4 carriers
(2.0 ± 1.1 vs. 2.2 ± 1.5 nmol/ml, respectively; p = 0.76).
Among APOE4 noncarriers and carriers, gray matter Jin
was 5.0 ± 3.3 vs. 6.3 ± 4.5 μmol/day/g, respectively (p =
0.49). With a mean whole brain volume of 1242 ml (cal-
culated by MRI), this DHA incorporation rate was
equivalent to a daily whole brain DHA incorporation rate
of 3.8 ± 2.5 mg/day for APOE4 noncarriers and 4.6 ±
3.3 mg/day for APOE4 carriers (p = 0.5). Gray matter Jin
was not significantly different between the APOE groups,
mainly because plasma DHA concentration had large vari-
ance in the two groups.
Cerebral blood flow
Neither mean overall gray matter nor medial temporal lobe
CBF differed significantly between the APOE subgroups
(global gray matter CBF 69.9 (16.7) ml×100 g-1 ×minute-1
in noncarriers vs. 71.4 (11.8) ml×100 g-1 ×minute-1 in
APOE4 carriers; p = 0.8). Mean gray matter and medial
temporal lobe k* did not correlate with the respective rCBF
(data not shown).
Discussion
In this exploratory post hoc analysis, we identified a sig-
nificantly greater mean global gray matter DHA incorp-
oration coefficient (k*) in APOE4 carriers compared with
noncarriers. This difference was present in several brain
regions, including the posterior cingulate cortex and the
medial temporal lobe. Within the medial temporal lobe,
higher DHA k* was prominent in the entorhinal cortex
area. The simplest explanation for the significantly
higher values of k* in APOE4 carriers is an increased in-
corporation by the brain from circulating unesterified
DHA, replacing DHA that is either metabolized to
Table 1 Participant characteristics
Group APOE4 noncarriers (n = 13) APOE4 carriers (n = 9) p Value
Female/male sex 8/5 2/7 0.07
White/nonwhite race 8/5 4/5 0.93
Age, years 37.1 (15.7) 32.1 (10.7) 0.39
Weight, kg 77.1 (15.7) 85.7 (20.4) 0.30
BMI, kg/m2 26.2 (4.2) 27.1 (5.0) 0.64
Systolic blood pressure, mmHg 111 (9.2) 118.4 (14.7) 0.35
Diastolic blood pressure, mmHg 60.3 (10.6) 62.8 (7.2) 0.61
Fasting glucose, mg/dl 94 (9.3) 90 (9.5) 0.37
Total cholesterol, mg/dl 162 (42.9) 168.1 (31.1) 0.70
HDL-C, mg/dl 49.8 (17.7) 53.7 (11.9) 0.54
LDL-C, mg/dl 98.3 (33.4) 101 (28.8) 0.84
Estimated DHA intake based on DHQ, mg/day 40 (41) 130 (120) 0.1
Brain volume, ml 1246 (150) 1232 (62) 0.76
Plasma APOE levels, μg/ml 15.8 (5.7) 10.7 (6.1) 0.06
Abbreviations: APOE Apolipoprotein E, APOE4 Apolipoprotein E ɛ4, BMI Body mass index, DHA Docosahexaenoic acid, DHQ Diet History Questionnaire, HDL-C High-
density lipoprotein cholesterol, LDL-C Low-density lipoprotein cholesterol
Values are presented as mean (SD). Groups were compared using an independent t test
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Fig. 2 Mean global brain (a) and medial temporal lobe (b) docosahexaenoic acid (DHA) incorporation coefficient k* by apolipoprotein E gene
(APOE) subgroups. Significantly greater DHA uptake was observed in APOE4 carriers than in noncarriers (*p≤ 0.05)
Table 2 Regional DHA k* by APOE subgroup (μl minute−1 ml−1)
Regions APOE4 noncarriers (n = 13) APOE4 carriers (n = 9) p Value Adjusted p valuea
Orbitofrontal 4.84 (1.25) 5.20 (0.59) 0.42 0.79
Prefrontal 3.81 (0.76) 4.37 (0.56) 0.07 0.12
Premotor 3.86 (0.73) 4.65 (0.51) 0.01 0.057
Anterior cingulate 2.76 (0.55) 3.27 (0.31) 0.02 0.088
Inferior temporal 3.56 (0.87) 3.96 (0.37) 0.21 0.56
Middle temporal 3.72 (0.83) 4.11 (0.39) 0.21 0.57
Superior temporal 3.42 (0.88) 3.69 (0.50) 0.41 0.87
Medial temporal 2.16 (0.45) 2.53 (0.33) 0.046 0.28
Sensorimotor 3.95 (0.84) 4.78 (0.52) 0.016 0.12
Inferior parietal 3.89 (0.87) 4.42 (0.46) 0.26 0.40
Superior parietal 4.38 (1.09) 4.81 (0.35) 0.26 0.59
Medial parietal 3.55 (0.88) 4.35 (0.38) 0.018 0.087
Posterior cingulate 3.09 (0.71) 4.00 (0.34) 0.002 0.02
Occipital association 3.98 (0.86) 4.81 (0.47) 0.016 0.12
Calcarine 4.41 (1.01) 5.07 (0.64) 0.098 0.35
Thalamus 3.90 (0.99) 4.62 (0.43) 0.053 0.06
Striatum 3.57 (0.95) 4.16 (0.84) 0.149 0.11
Cerebellar hemisphere 3.30 (0.82) 3.91 (0.53) 0.141 0.29
Vermis 2.97 (0.81) 3.60 (0.50) 0.051 0.046
Pure white matter 1.09 (0.41) 1.26 (0.16) 0.25 0.21
Average gray matter 3.64 (0.75) 4.23 (0.37) 0.04 0.19
APOE4 Apolipoprotein E ɛ4
Data are presented as mean (SD). Docosahexaenoic acid k* values were partial volume error-corrected. Groups were compared using a linear regression model.
Significantly differences (p < 0.05) by APOE group are shown in bold type
a Adjusted to age and sex
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bioactive products or lost to degradation. Given the
small sample size and the exploratory nature of this
study, these results are proof of concept and require
additional validation.
Vandal et al. reported reduced brain DHA levels in
older but not younger APOE4 mice compared with age-
matched APOE2 TR mice [20]. We recently reported
lower CSF DHA levels in older APOE4 carriers with AD
after 18 months of DHA supplementation than in
APOE4 noncarriers [21]. It is possible that the increased
k* represents a compensatory mechanism in younger
APOE4 carriers to cope with increased brain DHA loss
and to maintain brain DHA levels. This mechanism
might become impaired with aging, predisposing older
APOE4 carriers to reduced brain DHA levels and in-
creasing the risk for cognitive decline.
It is not possible on the basis of PET images to distin-
guish the exact metabolite explaining the higher incorp-
oration of DHA in the brain. The equation for
calculating k* assumes that all [1-11C]-DHA is irrevers-
ibly trapped in the brain and that no radioactive metab-
olite other than [11C]-CO2 crosses the blood-brain
barrier (BBB). This could result from more efficient
transport of unesterified DHA across the BBB, increased
activation of DHA to DHA-CoA by an acyl-CoA synthe-
tase, greater esterification into brain membrane lipid by
an acyltransferase, or decreased hydrolysis by phospho-
lipase A2 (PLA2) [26]. Any one of these steps could be
influenced by APOE genotype.
Several factors can alter k*. For example, k* was de-
creased in mice genetically lacking calcium-independent
PLA2β VIA [27], but it was increased when plasma and
brain DHA concentrations were reduced by chronic
dietary ω-3 PUFA deprivation in rats [17] or in subjects
with chronic alcoholism during acute withdrawal of al-
cohol [22]. Moreover, the DHA transport coefficient was
decreased with long-term high-DHA dietary consump-
tion [28]. Therefore, differences in habitual intake of
DHA may indirectly affect k*. To reduce variation in
DHA intake in the present study, participants were
instructed to avoid foods high in ω-3 PUFAs (e.g.,
seafood) 3 days preceding the PET scan, and they were
limited to one caffeinated beverage per day. Beginning
24 h before the PET scan, they consumed standardized
meals; in addition, they did not eat for 12 h prior to the
scan. The differences in plasma DHA levels or DHA
dietary intake were not significant by group.
The lower value of k* in the medial temporal cortex
is consistent with previous reports for [1-11C]- arachi-
donic acid and with values for rCBF [29, 30]. The
data likely reflect the unique architecture of this re-
gion, although there is some effect of the PVE correc-
tion [24]. We previously reported that lower plasma
levels of DHA were significantly associated with lower
entorhinal brain volumes in older cognitively healthy
adults with increased brain amyloidosis [13]. Higher
ω-3 content of red blood cells was also associated
with a lower rate of hippocampal atrophy [31]. Atro-
phy of this brain region predicts progression to AD
[32]. Therefore, understanding the mechanisms that
influence DHA metabolism in the medial temporal
cortex is of particular relevance to AD.
Higher regional k* among this relatively young adult
population of APOE4 carriers may provide one mechan-
ism for increased regional brain activation observed in
young adult APOE4 carriers [33–35]. One report dem-
onstrated differences in myelin structure and gray matter
volume in infants carrying the APOE4 allele [36]. Al-
though APOE4 is associated with increased risk for
memory decline and AD in older adults, several (but not
all) studies suggest a behavioral advantage in APOE4 for
younger carriers [37]. For example, in some studies,
APOE4 has been associated with higher IQ scores [38]
and a higher education level [39]. Advantageous effects
of the APOE4 allele have also been found for memory-
related functions in young animals. Hippocampal long-
term potentiation (LTP) was enhanced at a young age in
APOE4 TR mice compared with APOE4 noncarrier TR
mice [40]. This LTP enhancement was age-dependent
and disappeared in the adult mice. Mondadori et al.
found an association of APOE4 with better episodic
memory compared with APOE2 and APOE3 in 340
Table 3 Docosahexaenoic acid incorporation coefficient (k*, μl minute−1 ml−1) in medial temporal lobe subregions according to
APOE genotype
APOE4 noncarriers (n = 12) APOE4 carriers (n = 9) p Value
Hippocampus 2.69 (0.73) 2.86 (0.35) 0.43
Left 2.8 (0.80) 2.9 (0.4) 0.60
Right 2.6 (0.70) 2.8 (0.4) 0.47
Entorhinal cortex 2.77(0.10) 3.57 (0.67) 0.056
Left 2.6 (1.10) 3.2 (0.5) 0.16
Right 2.9 (1.0) 3.9 (1.2) 0.05
APOE Apolipoprotein E; APOE4 Apolipoprotein E ɛ4
Data are presented as mean (SD). Groups were compared using an independent t test
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young, healthy persons [41]. Dennis et al. found en-
hanced functional connectivity of the medial temporal
lobe with the posterior cingulate cortex in young adult
APOE4 carriers [34]. Rusted et al. reported that the
APOE4 in young adults was associated with improved
attention and enhanced connectivity [35]. Filippini et al.
reported increased default mode network coactivation in
APOE4 carriers relative to noncarriers using resting-
state functional MRI [33]. Combined, these findings sug-
gest a state of increased brain activity decades prior to
the onset of cognitive decline in APOE4 carriers. These
reports support the “antagonistic pleiotropy” hypothesis
in which cognitive advantages in younger adults support
higher achievement and greater selection benefits, but
may increase susceptibility to brain exhaustion and
memory failure with age [42]. In this context, one pos-
sible interpretation of the higher k* is that APOE4 is as-
sociated with greater brain DHA loss and greater
incorporation of DHA into the brain from plasma. These
findings would suggest a beneficial response in cognitive
function by increasing DHA consumption in APOE4
carriers in order to meet the greater metabolic demand
for DHA in the brain. Researchers in several epidemio-
logical studies and clinical trials have reported cognitive
benefit from increasing DHA consumption in cognitively
healthy APOE4 carriers [43]. This hypothesis merits add-
itional investigation.
The study has several limitations. The sample size was
small, and the study was a post hoc analysis of middle-
aged, predominantly white adults. We also did not have
sufficient participants to examine the effect of age or
separate homozygous from heterozygous APOE4 car-
riers. DHA incorporation into the brain may not be
dependent upon transport of peripheral lipoproteins;
thus, our observed differences may be due to APOE4-re-
lated differences in transport across the BBB, intracellu-
lar transport, metabolism, or degradation processes.
Unfortunately, data were not available to evaluate these
hypotheses.
Conclusions
To our knowledge, this is the first study describing
brain DHA incorporation coefficient in the context of
the APOE4 allele and shows that brain regions impli-
cated in the development of AD have different DHA
incorporation coefficients, depending on APOE status.
These findings support the development of novel
DHA uptake imaging modalities such as [18F]-DHA
to potentially accelerate the application of DHA im-
aging in clinical research. Knowledge of brain DHA
metabolism will enhance understanding of how the
APOE4 allele affects cognitive function and AD risk
across the lifespan.
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